Remdesivir becomes first anti-COVID-19 drug recommended by EU

The European MedicinesAdministration's EMA Human Drug Council (CHMP) supports the use of Gilead's Remdesivir for the treatment of patients with pneumonia with a new coronavirusCOVID-19infected within GileadThe move makes Remdesivir the first anti-COVID-19 drug to be approved by the European Unionthe recommendation is based on data from the NIAID-ACTT-11 study of the National Institute of Allergy and Infectious Diseases (NIAID), which found that patients treated with Remdesivir recovered about 11 days later and given a placebo for 15 daysbut the agency stressed that no efficacy was observed in mild to moderate patients: both the Remdesivir group and the placebo group recovered for five daysFor patients with severe illness (about 90 percent of the study population), the recovery time was 12 days for the Redseve group and 18 days for the placebo grouptaking into account the available data, CHMP believes that patients with pneumonia who need oxygen supplements can benefit from Remdesivir's treatment, i.epatients with severe COVID-19